Bionomics Limited, (BNOX): Price and Financial Metrics

Bionomics Limited, (BNOX): $0.20

0.00 (-1.06%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add BNOX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#242 of 336

in industry

BNOX Price/Volume Stats

Current price $0.20 52-week high $2.84
Prev. close $0.20 52-week low $0.18
Day low $0.19 Volume 490,200
Day high $0.20 Avg. volume 568,676
50-day MA $0.46 Dividend yield N/A
200-day MA $0.79 Market Cap 3.41M

BNOX Stock Price Chart Interactive Chart >


Bionomics Limited, (BNOX) Company Bio


Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.


BNOX Latest News Stream


Event/Time News Detail
Loading, please wait...

BNOX Latest Social Stream


Loading social stream, please wait...

View Full BNOX Social Stream

BNOX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!